// App-Quantinova.ai

PB1467 : Idelalisib Selectively Inhibits GPVI-mediated Platelet Activation and Shows Anti-atherothrombotic Activity

Researchers

Presenter

  • M. Nuez Barrachina

Principal Investigators

  • I. Izquierdo

  • L. Hermida-Nogueira

  • L. A. Morn

  • A. B. Arroyo

  • N. Garca-Barber

  • R. Gonzlez-Conejero

  • J. Rivera

  • C. Martnez

  • M. I. Loza

  • E. Domnguez

  • . Garca

Medical Centers

  • Hosp. Universitario Santiago de Compostela,, Santiago De Compostela, Spain

  • Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB‐Arrixaca, CB15/00055‐CIBERER, Murcia, Spain

  • University of Santiago de Compostela, Pharmacology Applied to Drug Discovery Group, Santiago de Compostela, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Idelalisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved